



Investment Process

We seek long-term investments in high-quality businesses exposed to structural growth themes that can be acquired at sensible valuations in a contrarian fashion and are led by excellent management teams.

Investing with Tailwinds

We identify structural themes at the intersection of growth and change with the objective of investing in companies having meaningful exposure to these trends. Themes can be identified from both bottom-up and top-down perspectives.

High-Quality Businesses

We seek future leaders with attractive growth characteristics that we can own for the long term. Our fundamental analysis focuses on those companies exhibiting unique and defensible business models, high barriers to entry, proven management teams, favorable positions within their industry value chains and high or improving returns on capital. In short, we look to invest in small companies that have potential to become large.

A Contrarian Approach to Valuation

We seek to invest in high-quality businesses in a contrarian fashion. Mismatches between stock price and long-term business value are created by market dislocations, temporary slowdowns in individual businesses or misperceptions in the investment community. We also examine business transformation brought about by management change or restructuring.

Manage Unique Risks of International Small- and Mid-Cap Equities

International small- and mid-cap equities are exposed to unique investment risks that require managing. We define risk as permanent loss of capital, not share price volatility. We manage this risk by having a long-term ownership focus, understanding the direct and indirect security risks for each business, constructing the portfolio on a well-diversified basis and sizing positions according to individual risk characteristics.

Team Overview

Our team is intellectually curious about the world and how it is changing. Each team member is passionate about small company investing and discovering businesses with meaningful and open-ended growth opportunities.

Portfolio Management



Rezo Kanovich
Portfolio Manager

Investment Results (%)

As of 30 June 2019	Average Annual Total Returns						
	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception ¹
Composite — Gross	7.29	24.06	—	—	—	—	24.06
Composite — Net	7.02	23.43	—	—	—	—	23.43
MSCI All Country World ex USA SMID Index	2.14	12.61	—	—	—	—	12.61
MSCI All Country World ex USA Small Cap Index	1.21	11.60	—	—	—	—	11.60

Annual Returns (%) 12 months ended 30 June

	2015	2016	2017	2018	2019
Composite — Gross	—	—	—	—	—

Source: Artisan Partners/MSCI. Returns for periods less than one year are not annualized. ¹Composite inception: 1 January 2019.

Past performance does not guarantee and is not a reliable indicator of future results. Current performance may be lower or higher than the performance shown. Composite performance has been presented in both gross and net of investment management fees. The portfolio's returns may vary greatly over shorter periods due to the limited operating period since inception.

Investment Risks: Investments will rise and fall with market fluctuations and investor capital is at risk. Investors investing in strategies denominated in non-local currency should be aware of the risk of currency exchange fluctuations that may cause a loss of principal. These risks, among others, are further described near the back of this document, which should be read in conjunction with this material.



Investing Environment

Global equities finished higher in Q2 as expectations for accommodative monetary policy and hopes for a long-term resolution to the protracted trade war between the US and China mitigated concerns about slowing global growth and reduced earnings estimates. The MSCI AC World ex USA SMID Index finished up 2.1%. On a regional basis, developed markets outperformed emerging markets as the latter were held back by weakness in China. By sector, returns were led by technology and industrials. Laggards were energy, consumer discretionary and consumer staples.

The macro backdrop is something we're aware of, particularly since it may provide us opportunities to invest at more attractive prices, but short-term market fluctuations are not a focus of our process. Instead, we spend our time looking for structural growth themes that will serve as tailwinds for our portfolio companies for many years to come. Accordingly, when we invest, we think about the opportunity over an investment horizon of five or more years. We seek a client base that values our approach and aligns with our long-term orientation.

Rather than focus on broad market volatility we continue to consistently apply our exclusionary approach. We look to identify a small subset of companies offering exposure to structural growth and possessing the requisite business quality characteristics. High-quality businesses, as we define them, are those with defensible business models, favorable positions in their industry value chains and strong management teams. We look for companies with meaningful competitive advantages such as technological leadership, intellectual property, strong brands or industries favoring natural monopolies. In short, we look for small companies with the ability to become meaningfully larger, and we look to acquire these businesses in a contrarian fashion in times of adversity by opportunistically taking advantage of price dislocations.

Finally, our universe allows us to create a diverse collection of themes and stocks. The success of these companies is much more a function of idiosyncratic factors, such as managements and technologies, rather than the cyclical market backdrop.

Performance Discussion

Our portfolio outpaced the MSCI ACWI ex USA SMID Index in Q2, adding to its sizable YTD performance advantage. Outperformance within our highly diversified portfolio was broad-based as several portfolio holdings across our varied structural growth themes contributed significantly to our quarterly return. In an environment of sluggish economic growth in many parts of the world, we're finding many interesting idiosyncratic ideas that are not macro-driven as we endeavor to manage a portfolio of low-correlated investments.

SolarEdge Technologies, Beijer Ref and Belimo were among our top individual performers; however, about two thirds of our portfolio holdings produced positive returns, with ~55 stocks generating double-digit gains. SolarEdge Technologies is an Israel-based producer of power conditioning equipment for solar photovoltaic

systems. The company makes semiconductor-based devices called inverters that are used to efficiently convert solar power—which can be volatile given cloud cover and shading—into an AC signal that is consumable by a power grid or storable in a battery. Following a period of underperformance driven by temporary component shortages and increased costs to implement rapid changes to the supply chain to account for trade policy uncertainty, shares rallied after the company demonstrated a recovery in margins and continued strong top-line growth. Our attraction to the company is focused on the high value-added position that its technology occupies within the solar power value chain, as well as its strong intellectual property. The company's technological leadership has led to rapid gains in market share in the residential solar market, and there remains significant opportunity in the commercial market. We are interested in alternative energy—and solar specifically—because the cost of solar, which is already on par with coal, continues to come down. We also expect that due to the company's expertise in power optimization, which is relevant in other fields (e.g., utility-scale solar, charging stations for electric vehicles, power storage applications), it can develop into a broader electrical engineering company.

Sweden-based Beijer Ref is one of the largest suppliers of HVAC and refrigeration solutions in Europe. The company has a number of characteristics that contribute to its attractiveness as an investment. First, it operates in a growth industry due to the push from changing regulation for environmental-friendly refrigerants, which Beijer Ref manufactures. In addition to the business's growth profile, we like several characteristics that we believe should contribute to long-term profits growth. First, the company is a high value-added distributor due to the technical expertise and support it provides as part of its consultative sales approach. For example, Beijer Ref helps its commercial and industrial customers determine what kind of refrigeration systems they should deploy. Second, Beijer Ref has a growing private-label manufacturing business across the refrigeration value chain featuring higher-margin environmentally friendly technology. Third, the company is expanding its presence geographically into Africa and the Asia-Pacific region.

Belimo is a Swiss engineering company that is a leading producer of actuators, control valves and sensors for HVAC, fire and safety systems. The company primarily supplies the non-residential market (~95% of company sales) consisting of commercial, governmental and industrial buildings. The company is known as an industry-leading innovator in the areas of smart buildings, including remote monitoring, temperature control, power efficiency and data monitoring to optimally run building systems. Our interest in the company stems from its technological leadership, strong brand and pricing power. This company also has the high-value bottleneck characteristic that we have discussed previously. Belimo benefits from pricing power because its products comprise a relatively small but critical part of building automation systems. Recent top-line growth has been better than underlying economic growth due in part to growth initiatives and product innovation, while free cash flow

generation has been strong despite investments in R&D and rising input costs.

Among our biggest QTD detractors were health care holdings Teva Pharmaceutical Industries, Intersect ENT and LivaNova. Teva shares came under pressure due to a two-pronged legal battle, including concerns about liability surrounding the opioid epidemic and allegations of drug-pricing collusion between Teva and other generic manufacturers. These issues have been in the headlines on and off the past few years, so we were aware they could resurface. While Teva has been investigated for price fixing by the DOJ since 2016, according to the company, it has not been contacted by the DOJ since these latest reports. This is an issue we are monitoring, but in our view, the more important legal controversy is the one related to the opioid epidemic. Teva and other health care companies, including distributors, have been sued by states under the nuisance law, alleging the companies contributed to the opioid epidemic in the US. Teva recently reached a settlement with the state of Oklahoma, and the market is extrapolating this settlement to the rest of the country. While these legal matters are ongoing, our investment case remains centered on a turnaround in Teva's business, a consolidation of its operating infrastructure and the emergence of a promising pipeline of assets in development. We, of course, continue to monitor the company's legal strategy, including via direct dialogue with Teva's leadership.

Intersect produces medical devices for the ear, nose and throat (ENT) market. The stock traded off on news that its CEO was stepping down to take a new position with Abbott Laboratories, creating a leadership vacuum in the interim. The announcement doesn't affect our fundamental views of the company. Intersect has a proven treatment for chronic sinusitis—a large market consisting of tens of millions of sufferers—called Sinuva™ that we believe has significant growth potential. Similar to stents, Sinuva™ is a self-expanding, bioabsorbable, drug-eluting implant that is well accepted in surgery. The treatment is gradually gaining acceptance, but we believe the company will require expanded insurance reimbursement for this sizable market to truly open.

LivaNova is a global medical technology company that produces devices for cardiac surgery, neuromodulation and cardiac rhythm management. Organic growth in neuromodulation—its biggest and most profitable segment—slowed due to competitive dynamics and sales force turnover. Epidiolex®, a new epilepsy drug sold by a competitor, likely contributed to weak sales of VNS (vagus nerve stimulation) implants used to prevent seizures. We don't believe Epidiolex® is an enduring threat, given the drug is not a cure for epilepsy, and VNS is typically used in combination with drug therapy.

Outlook and Positioning

We are pleased with our strong performance results for the Q2 and YTD periods and continue to be excited about the medium-term prospects of our portfolio companies. We are also not resting on our laurels. We continue to be active in our efforts to find high-quality small and mid-sized growth companies we can own for the long term.

We are traveling the world to find these ideas and are excited about the opportunities we have found. These trips have resulted in several additions to the portfolio that we are very excited about, including a UK video game company, a very interesting vaccines company in France, a specialty pharmaceuticals company focused on allergy vaccines based in Denmark, and an Australian telecommunications network provider focused on data center connectivity to name a few. We are building our positions in these companies gradually as we grow our knowledge base and look forward to reporting on them when their positions are more fully built.

Two of our biggest new purchases in Q2 were DSV and Petrobras Distribuidora. DSV is a leader in the freight-forwarding industry. We've gotten to know DSV from our investment in industry rival Panalpina. Panalpina is a stock we have owned in our logistics theme due to our long-standing interest in the freight-forwarding industry. We sold Panalpina after DSV agreed to acquire it during the quarter. The deal makes DSV the third-largest freight forwarder in the world. Although Panalpina was taken out at a large premium, we are excited by the acquisition, as a large portion of the deal consists of stock—thereby allowing Panalpina shareholders to participate in the upside of the investment case. We also think the transaction is a win-win for both companies. DSV has proven itself an acute consolidator in the space, having made several large acquisitions over the past decade in which it successfully extracted material revenue and cost synergies. Panalpina, on the other hand, has struggled to implement modern IT systems needed for today's on-demand supply chains. As a result, we believe there is potential for DSV to improve Panalpina's IT in addition to cutting costs, using scale to increase its pricing power and expanding its set of logistics services offerings and geographic reach.

Our purchase of Petrobras Distribuidora was the product of our last trip to Brazil. Our recent work there has been focused on the themes of digital payments and privatization. Our purchase of Petrobras Distribuidora relates to the latter. Brazil is beginning a wave of privatization of state-owned assets as it steers its economy toward a more market friendly stance and tries to reduce its budget deficit. During our recent trip there, we met several state-owned companies looking to privatize—including Petrobras Distribuidora, which is one of the largest chains of gas stations in the country. The company's profitability metrics have been subpar relative to competitors. Our investment case is that as a private company, it will have the independence to rationalize its cost structure and improve its corporate governance. We believe there is meaningful potential for increased profitability as corporate governance improves, regardless of whether there is an upturn in Brazil's economy—though an economic upturn would certainly add to its growth rate. Lastly, the company is investing in the renovation of the convenience stores at its gas stations, which has the potential to further drive growth and foot traffic.

We also meaningfully added to our existing position in Almirall, a Spanish pharmaceuticals company. Historically, Almirall was a sleepy,

family-owned business that lacked focus due to its multiple businesses, including a domestic business with a dominant sales force that was very stable but relatively low margin; a respiratory drug division that was sold to AstraZeneca in 2014; and a dermatology business. In the last few years, new management with a big pharma background has come in and made substantial changes. We are frequent investors in new management situations, as we've found they can be important catalysts for change. Since taking the helm Almirall's new management has rationalized the portfolio, divested the respiratory business and sold peripheral products in the dermatology portfolio that were diverting management's attention. Now the group is highly focused on the Spanish market and is a leading player in the global dermatology and aesthetics space. This is, in our view, a highly stable position from which to operate. We also like the company's robust pipeline of new drugs—including for psoriasis, actinic keratosis, acne and atopic dermatitis—and believe these products are underappreciated and have considerable growth potential.

Besides Panalpina, we also sold Israeli chip designer Mellanox Technologies after the announcement it would be acquired by Nvidia, a US semiconductor company. Other sales included Danish pharmaceuticals companies Ascendis Pharma and H. Lundbeck. We sold Ascendis Pharma because the stock price already reflected a positive outcome for an upcoming drug trial. Given the binary nature of the trial, its valuation no longer provided us a favorable risk-reward. H. Lundbeck is a company we've known and invested in for a long time. However, the recently installed management team's strategy is focused on purchasing pipeline products rather than internal R&D. Our historical interest in the company was oriented toward its R&D prowess, so we are less interested in this pivot toward an acquisition strategy. Lastly, we exited our position in Wartsila, a Finnish manufacturer of equipment for the marine and power generation markets, in favor of better opportunities with greater upside.

For more information: Visit www.artisanpartners.com

Investment Risks: International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period. These risks, among others, are further described in Artisan Partners Form ADV, which is available upon request.

Unless otherwise indicated, the Artisan Strategy characteristics relate to that of an investment composite or a representative account managed within a composite. It is intended to provide a general illustration of the investment strategy and considerations used by Artisan Partners in managing that strategy. Individual accounts may differ, at times significantly, from the reference data shown due to varying account restrictions, fees and expenses, and since-inception time periods, among others. Where applicable, this information is supplemental to, and not to be construed with, a current or prospective client's investment account information.

Securities of the same issuer are aggregated to determine a holding's weight in the portfolio. Securities referenced may not represent all of the securities in the portfolio. If certain information is unavailable for a particular security Artisan Partners may use data from a related security to calculate portfolio characteristics. All information in this report is as of the date shown in the upper right hand corner unless otherwise indicated and is subject to change without notice. Totals may not sum due to rounding.

Attribution is used to evaluate the investment management decisions which affected the portfolio's performance when compared to a benchmark index. Attribution is not exact, but should be considered an approximation of the relative contribution of each of the factors considered.

Net-of-fees composite returns were calculated using the highest model investment advisory fees applicable to portfolios within the composite. Fees may be higher for certain pooled vehicles and the composite may include accounts with performance-based fees. All performance results are net of commissions and transaction costs, and have been presented gross and net of investment advisory fees. Dividend income is recorded net of foreign withholding taxes on ex-dividend date or as soon after the ex-dividend date as the information becomes available to Artisan Partners. Interest income is recorded on the accrual basis. Performance results for the Index include reinvested dividends and are presented net of foreign withholding taxes but, unlike the portfolio's returns, do not reflect the payment of sales commissions or other expenses incurred in the purchase or sale of the securities included in the indices.

MSCI All Country World ex USA SMID Index measures the performance of small- and mid-cap companies in developed and emerging markets excluding the US. MSCI All Country World Small Cap Index measures the performance of small-cap companies in developed and emerging markets. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used to create indices or financial products. This report is not approved or produced by MSCI.

The Global Industry Classification Standard (GICS®) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

This summary represents the views of the portfolio manager as of 30 Jun 2019. Those views and portfolio holdings are subject to change and Artisan Partners disclaims any obligation to advise investors of such changes. The discussion of portfolio holdings does not constitute a recommendation of any individual security. For a complete list of holdings by contribution to the strategy, refer to the Contributors to Return chart.

Free Cash Flow is a measure of financial performance calculated as operating cash flow minus capital expenditures.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein. In no event shall Artisan Partners have any liability for direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) losses or any other damages resulting from the use of this material.

Artisan Partners Limited Partnership (APLP) is an investment adviser registered with the U.S. Securities and Exchange Commission (SEC). Artisan Partners UK LLP (APUK) is authorized and regulated by the Financial Conduct Authority and is a registered investment adviser with the SEC. APEL Financial Distribution Services Limited (AP Europe) is regulated by the Central Bank of Ireland. APLP, APUK and AP Europe are collectively, with their parent company and affiliates, referred to as Artisan Partners herein. Artisan Partners is not registered, authorised or eligible for an exemption from registration in all jurisdictions. Therefore, services described herein may not be available in certain jurisdictions. This material does not constitute an offer or solicitation where such actions are not authorised or lawful. Further limitations on the availability of products or services described herein may be imposed.

This material is only intended for investors which meet qualifications as institutional investors as defined in the applicable jurisdiction where this material is received, which includes only *Eligible Counterparties* as defined by the Markets in Financial Instruments Directive (MiFID) where this material is issued by APUK or AP Europe. This material is not for use by retail or professional clients and may not be reproduced or distributed without Artisan Partners' permission.

In the United Kingdom, issued by APUK, 25 St. James's St., Floor 3, London SW1A 1HA, registered in England and Wales (LLP No. 0C351201). Registered office: Reading Bridge House, Floor 4, George St., Reading, Berkshire RG1 8LS. In Ireland, issued by AP Europe. Location and registered office: Fitzwilliam Hall, Fitzwilliam Pl, Ste. 202, Dublin 2, D02 T292 (Company No. 637966).

Australia: This material is directed at wholesale clients only and is not intended for, or to be relied upon by, private individuals or retail investors. Artisan Partners Australia Pty Ltd is a representative of APLP (ARBN 153 777 292) and APUK (ARBN 603 522 649). APLP and APUK are respectively regulated under US and UK laws which differ from Australian laws and are exempt from the requirement to hold an Australian financial services license under the Australian Corporations Act 2001 in respect to financial services provided in Australia.

Bailiwick of Guernsey: The financial services referred to in this material and this document are not being made available in the Bailiwick of Guernsey (Guernsey) to more than 50 persons in Guernsey and the financial services may not be accepted by more than 50 persons in Guernsey.

Canada: This material is distributed in Canada by APLP and/or Artisan Partners Distributors LLC, which conduct activities in Canada under exemptions from the dealer, portfolio manager and investment fund manager registration requirements of applicable Canadian securities laws. This material does not constitute an offer of services in circumstances where such exemptions are not available. APLP advisory services are available only to investors that qualify as "permitted clients" under applicable Canadian securities laws.

© 2019 Artisan Partners. All rights reserved.

For US Institutional Investors and MiFID Eligible Counterparties — Not for Onward Distribution



Artisan Non-U.S. Small-Mid Growth Strategy

Quarterly Contribution to Return (%)

As of 30 June 2019

Top Contributors	Average Weight	Contribution to Return	Ending Weight
SolarEdge Technologies Inc	1.17	0.59	1.43
Beijer Ref AB	1.02	0.42	1.12
Nice Ltd	2.84	0.33	2.75
Belimo Holding AG	1.33	0.32	1.46
Gardner Denver Holdings Inc	1.28	0.28	1.31
XING SE	1.19	0.27	1.26
CAE Inc	1.33	0.27	1.40
AVEVA Group PLC	1.25	0.27	1.37
IMCD NV	1.21	0.25	1.27
Rakus Co Ltd	0.79	0.24	0.92
Jeol Ltd	1.10	0.24	1.18
Koninklijke DSM NV	1.54	0.23	1.56
Tecan Group AG	2.16	0.23	2.28
Obic Co Ltd	1.83	0.22	1.74
Kobe Bussan Co Ltd	0.84	0.21	0.91
MIPS AB	0.60	0.20	0.66
Metso OYJ	1.23	0.20	1.26
Carl Zeiss Meditec AG	1.05	0.17	1.05
Hypoport AG	0.54	0.17	0.62
Spirax-Sarco Engineering PLC	0.68	0.16	0.70
Altus Group Ltd	0.65	0.16	0.97
Abcam PLC	0.65	0.15	0.67
Panalpina Welttransport Holding AG	0.36	0.15	0.00
Notre Dame Intermedica Participacoes SA	0.60	0.14	0.64
Ossur HF	0.96	0.14	0.97
Almirall SA	1.23	0.14	1.45
NanoString Technologies Inc	0.61	0.14	0.59
Electrocomponents PLC	1.23	0.14	1.19
Baloise Holding AG	1.24	0.14	1.23
Morinaga & Co Ltd	1.02	0.13	1.11
Fuji Soft Inc	1.18	0.13	1.28
Cellavision AB	0.82	0.12	0.82
Megaport Ltd	0.25	0.12	0.29
SCSK Corp	1.11	0.11	1.11
OBIC Business Consultants Co Ltd	1.11	0.11	1.15
Fortnox AB	0.29	0.11	0.34
Ariake Japan Co Ltd	0.64	0.11	0.63
Cellnex Telecom SA	0.46	0.11	0.43
JD Sports Fashion PLC	0.78	0.11	0.73
Elekta AB	0.66	0.11	0.74
Argenx SE	0.79	0.11	0.85
HomeServe PLC	0.81	0.11	0.79
Lonza Group AG	1.08	0.10	1.11
Morneau Shepell Inc	0.94	0.10	0.94
Symrise AG	1.13	0.09	1.09
ViewRay Inc	0.52	0.09	0.47
Moneysupermarket.com Group PLC	0.63	0.09	0.67
Thule Group AB	0.87	0.09	0.85
Rohm Co Ltd	1.12	0.09	1.08
boohoo Group PLC	0.87	0.08	0.78
Rumo SA	0.80	0.08	0.87
DSV A/S	0.34	0.07	0.79
Azbil Corp	1.52	0.07	1.49

Continued on next page.

Bottom Contributors	Average Weight	Contribution to Return	Ending Weight
Teva Pharmaceutical Industries Ltd	0.83	-0.46	0.61
Intersect ENT Inc	0.65	-0.23	0.52
LivaNova PLC	0.64	-0.21	0.60
BlackBerry Ltd	0.58	-0.18	0.47
InflaRx NV	0.17	-0.17	0.00
B&M European Value Retail SA	1.15	-0.13	0.97
Jenoptik AG	1.06	-0.13	0.91
Britvic PLC	1.34	-0.12	1.22
Boozt AB	0.37	-0.10	0.14
ASOS PLC	0.55	-0.08	0.35
Heron Therapeutics Inc	0.22	-0.08	0.30
Orchard Therapeutics plc	0.20	-0.07	0.16
Hookipa Pharma Inc	0.08	-0.07	0.05
Yamaha Corp	1.23	-0.06	1.13
Blue Prism Group PLC	0.36	-0.06	0.25
Tech Mahindra Ltd	0.67	-0.05	0.56
Yokogawa Electric Corp	0.92	-0.05	0.87
Sagami Rubber Industries Co Ltd	0.42	-0.05	0.38
Biotage AB	0.69	-0.05	0.61
Joules Group PLC	0.27	-0.04	0.23
Radware Ltd	0.70	-0.04	0.73
SSP Group PLC	1.30	-0.04	1.21
SG Holdings Co Ltd	2.09	-0.03	2.15
Cognex Corp	0.58	-0.03	0.54
Nippon Shinyaku Co Ltd	0.76	-0.03	0.73
H Lundbeck A/S	0.28	-0.03	0.00
Fluidigm Corp	0.35	-0.02	0.33
Aston Martin Lagonda Global Holdings PLC	0.52	-0.02	0.50
Valneva SE	0.18	-0.02	0.23
Amarin Corp PLC	0.20	-0.02	0.20
Oxford Biomedica PLC	0.25	-0.01	0.23
Burckhardt Compression Holding AG	0.70	-0.01	0.64
Codemasters Group Holdings PLC	0.09	-0.01	0.57
Boku Inc	0.16	-0.01	0.12
Cree Inc	1.78	-0.01	1.62
JCR Pharmaceuticals Co Ltd	0.46	-0.01	0.43
Metro Bank PLC	0.07	-0.01	0.00
Treasury Wine Estates Ltd	0.99	-0.00	0.88
Gerresheimer AG	0.54	-0.00	0.51
Ascendis Pharma A/S	0.01	-0.00	0.00
Mellanox Technologies Ltd	0.01	-0.00	0.00
Wartsila OYJ Abp	0.17	-0.00	0.00
SimCorp A/S	0.75	-0.00	0.71
ACADIA Pharmaceuticals Inc	0.97	-0.00	0.98
AC Immune SA	0.08	0.01	0.08
Galapagos NV	0.08	0.01	0.07
IPG Photonics Corp	0.32	0.01	0.31
Davide Campari-Milano SpA	1.43	0.01	1.29
SailPoint Technologies Holding Inc	0.13	0.01	0.24
Petrobras Distribuidora SA	0.06	0.01	0.39
Kinaxis Inc	0.19	0.01	0.23
Basler AG	0.47	0.01	0.44
ConvaTec Group PLC	0.69	0.01	0.67

Artisan Non-U.S. Small-Mid Growth Strategy

Quarterly Contribution to Return (%)

As of 30 June 2019

Top Contributors (continued)	Average Weight	Contribution to Return	Ending Weight
Harmonic Drive Systems Inc	0.53	0.07	0.52
Carlsberg A/S	1.15	0.07	1.14
IMI PLC	0.78	0.07	0.77
St James's Place PLC	0.71	0.05	0.68
Rotork PLC	0.44	0.05	0.43
Salvatore Ferragamo SpA	0.35	0.05	0.36
Genmab A/S	0.77	0.04	0.77
Vericel Corp	0.48	0.04	0.55
AIXTRON SE	0.69	0.04	0.61
Howden Joinery Group PLC	1.05	0.04	0.98
Rohto Pharmaceutical Co Ltd	0.64	0.04	0.61
NuFlare Technology Inc	0.33	0.04	0.32
YouGov PLC	0.59	0.04	0.54
Lectra	0.42	0.03	0.43

Bottom Contributors (continued)	Average Weight	Contribution to Return	Ending Weight
Ypsomed Holding AG	0.25	0.01	0.32
DBV Technologies SA	0.20	0.01	0.18
The Descartes Systems Group Inc	0.67	0.02	0.60
ALK-Abello A/S	0.11	0.02	0.29
Quotient Ltd	0.42	0.02	0.44
Vestas Wind Systems A/S	0.41	0.02	0.39
BK Brasil Operacao e Assessoria a Restaurantes SA	0.82	0.02	0.82
Cash Holdings	3.90	0.02	4.00
Odonate Therapeutics Inc	0.00	0.02	0.18
MonotaRO Co Ltd	0.23	0.02	0.24
Auto Trader Group PLC	0.79	0.02	0.72
Grupo Catalana Occidente SA	0.57	0.03	0.56
MorphoSys AG	0.53	0.03	0.57
Linx SA	0.16	0.03	0.25

Source: Artisan Partners/FactSet. Performance is historical and is not a reliable indicator of future results. As of 30 Jun 2019. These investments made the greatest contribution to, or detracted most from, performance during the period based on a representative account within the strategy Composite. Upon request, Artisan will provide: (i) the calculation methodology and/or (ii) a list showing the contribution of each holding to overall performance during the measurement period. Securities of the same issuer are aggregated to determine the weight in the portfolio. % Contribution to Return is calculated by FactSet by multiplying a security's weight in the portfolio by its in portfolio return for the period referenced and does not take into account expenses of the portfolio. Purchases/sales are accounted for by using end of the day prices, which may or may not reflect the actual purchase/sale price realized by the portfolio.